About this Antibody |
Name | Recombinant Human Proinsulin C-Peptide Analogue (Recombinant Human Proinsulin C-Peptide Analogue; rHuProinsulin C-Peptide Analogue);重组人胰岛素原C肽类似物 |
Synonyms | IDDM2; ILPR; insulin; IRDN; MODY10; proinsulin |
Purity | >95% by SDS-PAGE and HPLC analyses. |
Biological Activity | Data Not Available. |
Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
Formulation | Lyophilized from a 0.2μm filtered solution in PBS, pH7.4. |
Endotoxin | Less than 0.1EU/μg of rHuProinsulin C-Peptide Analogue as determined by LAL method. |
Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions. |
Category | Cytokine |
Background | Proinsulin, a molecular weight of 8kDa to 10kDa, is a precursor of insulin. It has minimum hormonal activity and is converted to insulin by removal of the connecting C-peptide. Mature insulin has 35 fewer amino acids; 4 are removed altogether and the remaining 31 form the C-peptide. The C-peptide is abstracted from the center of the proinsulin sequence; the two other ends (the B chain and A chain) remain connected by disulfide bonds. Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle and glycogen synthesis in liver. |
Amino Acid Sequence | RREAEDLQVG QVELGGGPGA GSLQPLALEG SLQKR |